Experimental cell therapy for resistant autoimmune kidney disease
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests an experimental cell therapy (CAR-γδ T cells) for people with certain autoimmune kidney diseases that have not responded to usual treatments. The goal is to see if this therapy is safe and can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 65 years old.
- You must have one of these kidney diseases: primary membranous nephropathy, lupus nephritis, or IgA nephropathy.
- Your kidney disease must have gotten worse or not improved after at least 6 months of standard treatment.
- You must have had a kidney biopsy within the last 18 months to confirm your diagnosis.
- You must not have active infections like hepatitis B or C, HIV, or active tuberculosis.
- You must not be pregnant or breastfeeding and must agree to use contraception for at least 1 year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell treatment (CAR-T) for people with certain kidney diseases—IgA nephropathy or membranous nephropathy—that have not improved with standard care. The therapy aims to calm the immune system to protect the kidneys.
This trial tests a new cell therapy called GT719 that targets B cells, part of the immune system that attacks the kidneys in several types of autoimmune kidney disease. It is designed for people whose kidney disease has not improved with standard treatments.
This trial tests a new treatment called CD19 CAR-T cell therapy for people with severe lupus nephritis (lupus-related kidney inflammation) that hasn't improved with usual treatments. The therapy uses your own immune cells to target and possibly reset the immune system, which may reduce kidney damage and help control the disease.
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
This trial tests a new treatment called ICG318 CAR-T, which uses your own immune cells to target and calm the overactive immune system in lupus. It may help people whose lupus has not improved with standard treatments, including those with lupus nephritis (kidney inflammation).
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hear when a new Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.